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The cholesterol biosynthetic pathway produces not only
sterols but also non-sterol mevalonate metabolites involved
in isoprenoid synthesis. Mevalonate metabolites affect trans-
criptional and post-transcriptional events that in turn affect
various biological processes including energy metabolism. In
the present study, we examine whether mevalonate metabolites
activate PPARγ (peroxisome-proliferator-activated receptor γ),
a ligand-dependent transcription factor playing a central role
in adipocyte differentiation. In the luciferase reporter assay
using both GAL4 chimaera and full-length PPARγ systems, a
mevalonate metabolite, FPP (farnesyl pyrophosphate), which is
the precursor of almost all isoprenoids and is positioned at branch
points leading to the synthesis of other longer-chain isoprenoids,
activated PPARγ in a dose-dependent manner. FPP induced the
in vitro binding of a co-activator, SRC-1 (steroid receptor co-
activator-1), to GST (glutathione transferase)–PPARγ. Direct
binding of FPP to PPARγ was also indicated by docking
simulationstudies.Moreover,theadditionofFPPup-regulatedthe
mRNAexpressionlevelsofPPARγ targetgenesduringadipocyte
differentiation induction. In the presence of lovastatin, an HMG-
CoA(3-hydroxy-3-methylglutaryl-CoA)reductaseinhibitor,both
intracellular FPP levels and PPARγ-target gene expressions were
decreased. In contrast, the increase in intracellular FPP level after
the addition of zaragozic acid, a squalene synthase inhibitor,
induced PPARγ-target gene expression. The addition of FPP
and zaragozic acid promotes lipid accumulation during adipocyte
differentiation. These ﬁndings indicated that FPP might function
as an endogenous PPARγ agonist and regulate gene expression
in adipocytes.
Key words: adipocyte differentiation, farnesyl pyrophosphate
(FPP), ligand, metabolic syndrome, mevalonate metabolite,
peroxisome-proliferator-activated receptor γ (PPARγ).
INTRODUCTION
The pathophysiology of obesity and obesity-associated metabolic
disorders including Type 2 diabetes mellitus, hypertension,
hyperlipidaemia and cardiovascular disease is associated with
abnormalities in endocrine signalling in WAT (white adipose
tissue) [1,2]. The expansion of WAT during the development of
obesity can occur through an increases in cell number and cell
size[3].ThereforethemechanismscontrollingWATdevelopment
have been the focus of intense research.
Thenumberofadipocytesisthoughttoincreaseasaresultofthe
proliferationofpre-adipocytesandsubsequentdifferentiationinto
mature adipocytes [4]. Adipocyte differentiation is characterized
by marked changes in the pattern of gene expression that are
achieved by sequential induction of various transcription factors
[4]. PPARγ (peroxisome-proliferator-activated receptor γ), a
member of the nuclear hormone receptor superfamily, plays a
central role in the regulation of adipocyte differentiation [4].
PPARγ is a ligand-dependent transcription factor binding to
the promoter of its target genes only as a heterodimer with
RXR (retinoid X receptor) [4,5]. The thiazolidinediones, insulin
sensitizers, promote the differentiation of pre-adipocytes by
PPARγ activation [4] to increase the number of small adipocytes
and to decrease the number of large adipocytes by increasing
apoptosis[6],resultingintheimprovementofmetabolicdisorders,
such as insulin resistance. Although several naturally occurring
compounds have been reported to activate PPARγ, the levels of
these PPARγ ligands in tissue and plasma are frequently not
precisely deﬁned and, when so, are found at levels sometimes
orders of magnitude lower than those required to activate speciﬁc
α,γ orδ PPARsubtypes[7–9].Thustheidentiﬁcationofbonaﬁde
high-afﬁnityendogenousPPARγ ligandshasbeenacontroversial
issue that, when resolved, will advance our understanding of
PPARγ modulationandrevealnewwaysofinterventionindiverse
metabolic disorders and disease processes.
Non-sterol mevalonate metabolites involved in isoprenoid
synthesis have until recently mainly been associated with the
regulationofcell-cyclecontrolandcytoskeletalorganization[10].
Moreover, the mevalonate pathway in mammals has been shown
to affect several nuclear hormone receptors (such as PPARα,
PPARγ andliverXreceptors)thatregulatelipidandcarbohydrate
metabolism [11–14]. Previously, we have demonstrated that
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severalisoprenoidscontainedinherbalanddietaryplantsfunction
as PPAR ligands [15–19]. In the present paper, we report that
FPP (farnesyl pyrophosphate), which is a mevalonate metabolite
and the precursor of almost all isoprenoids, can activate PPARγ
as an agonist and regulate the expression levels of PPARγ target
genesduringadipocytedifferentiation.Theseﬁndingssuggestthat
FPP may function as an endogenous PPARγ ligand and regulate
adipocyte functions.
MATERIALS AND METHODS
Materials
FPP was from Wako Pure Chemicals (Osaka, Japan). LG100268
and lovastatin were purchased from Santa Cruz Biotechnology
and Calbiochem (San Diego, CA, U.S.A.). Unless otherwise
indicated, all chemicals were purchased from Sigma or Nacalai
Tesque (Kyoto, Japan) and were of guaranteed reagent grade or
tissue culture grade.
Cell culture
3T3-L1 murine pre-adipocytes (from A.T.C.C., Manassas,
VA, U.S.A.) were cultured in a growth medium, DMEM
(Dulbecco’s modiﬁed Eagle’s medium) supplemented with
10% (v/v) fetal bovine serum, 100 units/ml penicillin and
100 μg/ml streptomycin at 37◦Ci n5 % CO2. At 2 days after
reaching conﬂuence, the cells were incubated in a differentiation
medium containing 0.25 μM dexamethazone, 10 μg/ml insulin
and 0.5 mM IBMX (1-methyl-3-isobutylxanthine) in the growth
medium with or without indicated compounds. After 48 h, the
cells were harvested for mRNA expression level analysis. For the
fatty acid synthesis activity assay and Oil Red O staining, 3T3-L1
cells, whose differentiation was induced as described above, were
maintainedforanother2–8 daysinthegrowthmediumcontaining
insulin (5 μg/ml) with or without FPP or Pio (pioglitazone).
Monkey CV1 kidney cells and murine NIH 3T3 ﬁbroblasts
were cultured in the growth medium at 37◦Ci n5% CO2.
Luciferase assay
A luciferase assay was performed as described previously [11–
15]. Brieﬂy, for the luciferase assay using GAL4 chimaera
systems, we transfected p4xUASg-tk-luc (a reporter plasmid),
pM-hPPARγ or pM-hRXRα (an expression plasmid for a
chimaeraproteinfortheGAL4DNA-bindingdomain,andhuman
PPARγ-o rR X R α-ligand-binding domains) and pRL-CMV
(an internal control for normalizing transfection efﬁciencies)
into CV1 cells. For luciferase assays using a PPARγ full-
length system, pDEST-hPPARγ (a human PPARγ expression
vector),areporterplasmid(p3xPPRE-tk-luc)andpRL-CMVwere
transfected into CV1 cells. Transfections into CV1 cells cultured
on 100 mm dishes were performed using Lipofectamine
TM
(Invitrogen)accordingtothemanufacturer’sprotocol.At5 hafter
the transfections, the transfected cells were seeded on to 96-
well plates with the medium containing each compound. After
a 24 h incubation, a luciferase assay was performed using the
dual-luciferasesystem(Promega)accordingtothemanufacturer’s
protocol.
GST (glutathione transferase) pull-down assay
A GST pull-down assay was performed as described previously
[12].Brieﬂy,forexpressionofthefull-lengthPPARγ–GSTfusion
protein, the pDEST15 vector (Invitrogen) was used. Glutathione–
Sepharose 4B (Amersham Biosciences) was washed extensively
in binding buffer (10 mM Tris/HCl, pH 7.4, 1 mM EDTA,
150 mMNaCl,1 mMdithiothreitoland10%glycerol)containing
anappropriateconcentrationofproteaseinhibitorcocktail(Roche
Diagnostics, Mannheim, Germany) and resuspended in a volume
of the binding buffer sufﬁcient to generate a 50% slurry. This
slurry was mixed with each cell lysate of Escherichia coli
expressing GST or human PPARγ–GST and incubated at 4◦C
overnight. The resin slurry was gently centrifuged, washed ﬁve
times in the binding buffer to remove all unbound proteins and
ﬁnally resuspended in 1 volume of the binding buffer. The
GST pull-down experiments were conducted using 40 μlo f
GST-bound or GST–hPPARγ-bound, and unbound glutathione–
Sepharose slurries and 20 μl of SRC-1-S2, a truncated SRC-
1 (steroid receptor co-activator-1) protein (amino acids 623–
770) produced by RTS500HY E. coli (Roche Diagnostics).
After incubation for 2 h at 4◦C with continuous rotation, the
samples were gently centrifuged and washed ﬁve times in the
binding buffer. After the ﬁnal wash, the resin was resuspended
in 30 μl of SDS/PAGE sample buffer (Bio-Rad). Each sample
was electrophoresed on a 7% denaturing gel. After blotting on
to PVDF membranes, an enhanced chemiluminescence system
(NENLifescienceProducts)wasusedtodetecttheSRC-1protein
binding to the PPARγ–GST protein. The density of protein bands
was measured using the density analysis software NIH Image, as
described previously [20].
Co-activator recruitment assay
The ﬂuorescence polarization assay for SRC-1/PPARγ binding
was performed as described previously [21]. The PPAR-
binding site (amino acids 623–770) of human SRC-1 was
cloned into pROX-FL92 (Protein Express, Choshi, Japan).
This expression vector enabled the addition of the FL tag
of 12 amino acids [22] and the His tag to upstream and
downstream of SRC-1 respectively. With an umber codon
inserted during the addition of the FL tag and CloveDirect
TAMRA (6-carboxytetramethylrhodamine; Protein Express),
the pinpoint ﬂuorescent labelling protein to which TAMRA-
aminophenylalanine was introduced into the ninth amino acid
was produced. By adding pROX-FL92-SRC-1 and CloveDirect
TAMRA to the RST100 E. coli HY system (Roche Diagnostics),
TAMRA-probed SRC-1 was expressed and puriﬁed. The mixture
of 250 nM GST–PPARγ and 5 nM pinpoint ﬂuorescent labelling
SRC-1 (TAMRA–SRC-1) was added with 1–100 μM ligands.
After a 1 h reaction, ﬂuorescence polarization was monitored for
10 s, and the monitoring was repeated ﬁve times. Excitation and
emission wavelengths were set at 555 and 580 nm respectively.
ByScatchardanalysisandHillanalysis,thedissociationconstants
of the PPARγ ligand and SRC-1 complex were estimated.
For the CBP [CREB (cAMP-response-element-binding
protein)-binding protein]/PPARγ binding assay, we used a
commercial ELISA kit (Fujikura Kasei, Tokyo, Japan).
Docking simulation study
From among the substrates of PPARγ complexes contained in
the PDB, 5HE (5-hydroxyeicosapentaenoic acid) was selected on
the basis of its similarity to FPP in terms of relevant factors,
such as molecular length, molecular shape and the position of
a polar group. The steric structure of the protein registered in
PDB with the 2VV2 code was used for the molecular modelling
of FPP in complex with PPARγ. In the model, the carboxylic
acid of 5HE was substituted by phosphoric acid at the end of
FPP; the OH group at the ﬁfth carbon of 5HE was substituted
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by a second oxygen atom in phosphoric acid. The remaining part
of the alkyl chain was aligned along the unsaturated hydrocarbon
chainof5HE.Usingthismodelasaninitialstructure(Figure3A),
we carried out MD (molecular dynamics) simulation to examine
the binding state of FPP. For comparison, the MD simulation
of 5HE was also carried out to examine the binding stability of
FPP. To construct the MD simulation system with the periodic
boundary condition, each of these two complexes was placed
in a cubic box (size of approximately 92 Å
3;1Å= 0.1 nm)
ﬁlled with water molecules, and in order to neutralize this system,
Na
+ ions and Cl
− ions were included, for which the program
AMBER 9 [23] was used. The total number of water molecules
was approximately 10100. We used the uniﬁed force-ﬁeld model
[24] of GAFF parameters [25] and RESP charges [26] for PPARγ
withthemodiﬁedtopologyﬁleusinganin-houseprogram,GAFF
parameters and AM1-BCC charges [27,28] for FPP and 5HE, and
the TIP3P model [26] for water. To accelerate the calculation,
a special-purpose parallel computer for non-bonded force sum,
MD Server (http://www.nec.co.jp/press/en/0511/2901.html), was
used. Temperature and pressure were controlled at 300 K and
1 atm respectively. The time step was 2 fs with the bond-
length constraints for hydrogen atoms, and the simulation of each
system was performed for 7500000 steps (corresponding to MD
simulation of 15000 ps).
Stable isotope-based fatty acid synthesis activity assay
Cells were washed with warm PBS, and the medium was
replaced with glucose-free DMEM containing 4.5 mg/ml [
13C6]-
glucose. After a 48 h incubation, the medium was collected and
diluted with methanol. Diluents were ﬁltered using a 0.22 μm
ﬁlter membrane, and ﬁltrates were analysed using the LC/MS
(liquid chromatography MS) system (Agilent Series 1100 LC
system; Agilent Technologies, Waldbronn, Germany). Cells were
dissolved in 5 ml of 20% KOH [ethanol/water (4:6, v/v)],
hydrolysed for 60 min at 80◦C and then acidiﬁed with 6 ml of
5 M HCl. Fatty acids were extracted twice with 4 ml of diethyl
ether, dried under N2 at 40◦C, dissolved in 5 ml of methanol and
analysed using the LC/MS system.
Determination of FPP levels
Intracellular FPP levels were determined as described previously
[29]. Brieﬂy, NIH 3T3 cells cultured with each compound for
48 h in six-well plates were washed with PBS and collected.
The cells were then extracted with butanol/75 mM ammonium
hydroxide/ethanol (1:1.25:2.75, by vol.). After centrifugation,
the supernatants were dried under reduced pressure. The
resulting residue was then dissolved in 50 mM Tris/HCl assay
buffer (pH 7.5) containing 5 mM dithiothreitol, 5 mM MgCl2,
10 μMZnCl 2 and1.0%octyl-β-D-glucopyranoside.Dansylated-
GCVLS peptides (Hayashi Kasei, Osaka, Japan) and FPTase
(farnesyl pyrophosphate transferase) were added to the extracted
solution, and the assay mixture was then incubated at 38◦C
for 120 min. The reaction was terminated by the addition of
acetonitrile and hydrogen chloride. FPP mass-reacting with the
dansylatedsubstratepeptideascatalysedbyFPTasewasseparated
and quantiﬁed by HPLC coupled with a ﬂuorescence detector
at λex=335 nm and λem=528 nm using a C18 reversed-phase
analytical column.
Oil Red O staining
Cells were ﬁxed with 10% formaldehyde/PBS and stained with
Oil Red O solution (0.5% Oil Red O-isopropyl alcohol/water;
3:2, v/v). After staining, Oil Red O was extracted from cells with
isopropyl alcohol and the attenuance at 490 nm was measured.
Levels of Oil Red O staining were corrected for non-speciﬁc
binding levels of the stain to untreated cells.
RNA preparation and real-time ﬂuorescence monitoring RT–PCR
(reverse transcription–PCR)
Total RNA was prepared from 3T3-L1 cells using Sepasol®-
RNA I Super (Nacalai Tesuque) according to the manu-
facturer’s protocol. Total RNA was reverse-transcribed using
MMLV (Moloney-murine-leukaemia virus) reverse transcriptase
(Promega) according to the manufacturer’s instructions. To
quantify mRNA expression, real-time RT–PCR was performed
with a LightCycler system (Roche Diagnostics) using SYBR
green ﬂuorescence signals, as described previously [11–
15,20]. The oligonucleotide primers of mouse 36B4 and
adipogenic marker genes were designed using a PCR primer
selection program in the website of the Virtual Genomic
Center from the GenBank® Nucleotide Sequence Database.
Primer sets used to measure the expression levels of 36B4,
aP2 (adipocyte fatty-acid-binding protein), LPL (lipoprotein
lipase) and adiponectin, have been described previously
[11–15,20]. The primers used for the measurements of
GLUT4 (glucose transporter 4) mRNA expression levels up-
stream and downstream were 5
 -CGGATGCTATGGGTCCTTA-
CG-3
  and 5
 -TGAGATCTGGTCAAACGTCCG-3
  respectively.
To compare mRNA expression levels among the samples, the
copy numbers of all of the transcripts were divided by that of
mouse 36B4, showing a constant expression level in adipocytes.
All of the mRNA expression levels are presented here as the ratio
relative to that of the control in each experiment.
Statistical analysis
Theresultsarepresentedasmeans+ −S.E.M.andwerestatistically
analysed by the unpaired Student’s t test or the Welch t test
whenvarianceswereheterogeneous.Differenceswereconsidered
signiﬁcant when P was <0.05.
RESULTS
FPP activates PPARγ in the luciferase reporter assay
First, to examine whether mevalonate metabolites (Figure 1A)
affect PPARγ ligand activity, we performed a luciferase reporter
assay using the GAL4 chimaera system. In this assay system,
Pio (1 μM), a synthetic PPARγ agonist, signiﬁcantly enhanced
luciferase activity (Figure 1B). We evaluated PPARγ ligand
activity in the presence of various mevalonate metabolites at a
concentration of 1 μM. As shown in Figure 1(B), in the presence
of 1 μM FPP, luciferase activity was increased 4.4-fold compared
with the vehicle control, suggesting that FPP increased PPARγ
ligand activity. At this concentration, GGPP (geranylgeranyl
pyrophosphate) also activated PPARγ, but the activation induced
by GGPP was much weaker than that induced by FPP. Next, we
investigated by luciferase reporter assay whether FPP activates
full-length PPARγ. In this assay system, the addition of FPP
also increased luciferase activity in a dose-dependent manner,
suggesting that FPP activates full-length PPARγ (Figure 1C).
Because the agonists of RXRs, the heterodimer partners of
PPARγ, also activate full-length PPARγ [30], we evaluated the
effectofFPPonRXRα ligandactivitybyluciferasereporterassay
using the GAL4 chimaera system. As shown in Figure 1(D), FPP
activated PPARγ in a dose-dependent manner, whereas FPP had
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Figure 1 FPP activates PPARγ as shown by luciferase reporter assay
(A)Schematicillustrationofthemevalonatepathway.Thetargetsoflovastatinandzaragozicacid
are also shown. (B–D) Effects of mevalonate metabolites (1μM) or FPP on PPARγ or RXRα
activity in a luciferase reporter assay using the GAL4/PPARγ chimaera system (B), full-length
PPARγ system(C)orGAL4/PPARγ andGAL4/RXRαchimaerasystem(D).CV1monkeykidney
cells were transfected with pM-PPARγ, p4xUASg-tk-luc and pRL-CMV (B), pDEST-hPPARγ,
p3xPPRE-tk-luc and pRL-CMV (C), or pM-PPARγ/pM-RXRα, p4xUASg-tk-luc and pRL-CMV
(D). Cells were incubated in a medium with each mevalonate metabolite, Pio or LG100268 (LG;
a synthetic RXR agonist) for another 24h after the transfection. The activity of a vehicle control
wassetat100%andtheobtainedrelativeluciferaseactivitiesarepresentedasthefoldinduction
with respect to that in the vehicle control. All of the values are the means+ −S.E.M. for three or
four tests.
no effect on RXRα ligand activity. These ﬁndings indicate that
FPP increased PPARγ ligand activity followed by the activation
of PPARγ.
FPP binds directly to PPARγ as an agonist
To conﬁrm the direct effects of FPP on PPARγ activation, a GST
pull-down assay was performed. A co-activator, SRC-1, interacts
with PPAR proteins when the agonists of PPARs bind to the
PPAR-ligand-binding domain [31]. Therefore the in vitro binding
of SRC-1 to PPARs in the presence of a compound suggests
that the compound binds to PPARs as an agonist. Under these
conditions in the presence of 50 μMP i o ,aH i s - t a g g e dS R C - 1
fragment, bound to PPARγ, is shown in Figure 2(A). FPP
(100 μM) recruited the SRC-1 fragment on to PPARγ proteins
as well as Pio. The densities of the bands are presented
in Figure 2(B). The degrees of binding of SRC-1 to PPARγ in
t h ep r e s e n c eo f5 0μM Pio, and 50 and 100 μM FPP increased
17-, 6.1- and 15-fold respectively relative to that of the vehicle
control. This suggests that FPP as an agonist of PPARγ can
induce the binding of SRC-1 to PPARγ, which is important
for the ligand-dependent activation of PPARγ. Next, to study
co-activator recruitment to PPARγ kinetically, we performed
an in vitro recruitment assay using pinpoint ﬂuorescent labelling
SRC-1 and GST–PPARγ. FPP enhanced the interaction between
PPARγ and SRC-1 in a dose-dependent manner in a similar
mannertoPio.AsshowninFigure2(C),theScatchardplotshows
a straight line. Bmax (Xint) might be slightly different however;
we conﬁrmed that Bmax (polarization) was approx. 260 mP at
the maximum concentration in the case of all ligands, including
troglitazone and rosiglitazone. The dissociation constants of FPP
and Pio were estimated as 955 and 357 nM respectively. As
GGPP also activated PPARγ weakly in the luciferase assay
(Figure 1B), we performed a ﬂuorescence polarization assay for
SRC-1/PPARγ binding using GGPP. In that assay, we conﬁrmed
thatGGPPdidnotinduceaninteractionbetweenﬂuorescentSRC-
1a n dP P A R γ. Moreover, we investigated another co-activator,
CBP, for its recruitment to PPARγ. Similarly to SRC-1, CBP
interacts with PPARγ when the agonists of PPARs bind to the
PPAR-ligand-binding domain [32]. As is the case in SRC-1, FPP
induced the interaction between CBP and PPARγ (Figure 2D),
and this interaction was attenuated in the presence of GW9662, a
syntheticPPARγ antagonist,suggestingthatFPPbindstoPPARγ
speciﬁcally.
The X-ray crystal structure of the 5HE–PPARγ complex (PDB
code 2VV2) and the model structure of the FPP–PPARγ complex
shown in Figure 3(A) were subjected to MD simulation for
15000 ps to examine the binding stability of FPP. The RMSD
(root-mean-square displacement) of carbon atoms for 5HE and
FPP for 15000 ps, which is calculated with respect to the atomic
coordinatesat15000ps,isshowninFigure3(B).Afterthestartof
MD simulation, structural changes and positional displacements
were induced in the initial structure for both 5HE and FPP. The
structure of 5HE reached a steady state and position in approx.
5000 ps, whereas that of FPP reached a steady state and position
in approx. 3000 ps. After the elapse of these times, both 5HE and
FPPretainedstructuralstabilityforthesubsequent10000psinthe
presence of thermal ﬂuctuation alone. For both 5HE–PPARγ and
FPP–PPARγ complexes,thesteady-stateCα RMSDwasconstant
at approx. 1.1 Å. On the basis of these ﬁndings, the FPP–PPARγ
complex shows the same level of stability as the 5HE–PPARγ
complex on the time scale of this MD simulation. In Figure 3(C),
the binding state of the initial model is compared with that of the
MD-simulated model at15000ps.Thepositions ofthephosphate
group are the same in both models, whereas the structures of the
carbon chain are slightly different. These ﬁndings indicate that
FPP can directly bind to PPARγ as its agonist.
The addition of FPP up-regulated PPARγ target genes during
induction of adipocyte differentiation
To elucidate whether FPP actually induces PPARγ target gene
expression during the induction of adipocyte differentiation, we
evaluated mRNA expression levels using 3T3-L1 pre-adipocytes.
Adipocyte differentiation was induced by the addition of a
standard adipogenic mixture of dexamethasone, insulin and
IBMX and an incubation for 48 h. FPP or Pio (a synthetic PPARγ
agonist) was also added with this standard adipogenic mixture,
and after 48 h, mRNA expression levels were measured. In the
presence of 5 μM Pio, well-known PPARγ target genes, such
as aP2, LPL and adiponectin, in adipocytes were induced 7.3-,
2.8- and 1.5-fold respectively (Figures 4A–4C). The addition of
FPP also increased the mRNA expression levels of these genes
in a dose-dependent manner (Figures 4A–4C). Treatment with
1 μM FPP resulted in 3.1-, 2.2- and 2.4-fold increases in aP2,
LPLandadiponectinlevelsrespectively.Moreover,theexpression
levels of GLUT4, which encodes the insulin-sensitive GLUT
induced by PPARγ activation [33], were increased by both FPP
and Pio (Figure 4D). These ﬁndings indicate that FPP treatment
enhances PPARγ target gene expression and promotes adipocyte
differentiation.
Next, we estimated the rate of de novo fatty acid synthesis
from glucose after chronic FPP treatment using [
13C6]-glucose
and the LC/MS system. In the case of FPP addition to the
medium throughout the differentiation period (day 0–10), total
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Figure 2 FPP induces the recruitment of co-activators to PPARγ in vitro
(A)GSTpull-downassayusingfull-lengthPPARγ protein.RecombinantSRC-1fragment(SRC-1-S2)containingaPPAR-bindingregionwasincubatedwithGST–humanPPARγ andvehiclecontrol,
50μM Pio or 50μM/100μM FPP. After washing, the bound recombinant SRC-1 protein was detected by immunoblotting. Total GST–PPARγ protein was detected by Coomassie Brilliant Blue
staining. The results are representative of three independent blots. (B) The densitometric analysis of immunoblotting membranes normalized by the amount of GST–PPARγ of (A) is shown. The
density of the vehicle control was set at 1 and the relative densities were presented as the fold induction relative to that of the vehicle control. (C) Scatchard plot analysis of the binding of a PPARγ
triangles ligand complex to the TAMRA–SRC-1 in the presence of pioglitazone (Pro; closed triangles) or FPP (closed circles). As the control experiment, TAMRA–SRC-1 was incubated together with
GST protein. Ligand concentrations (in μM) at all data points are 0.15, 1.0, 2.0 and 3.8 for FPP and 0.1, 0.4, 1.2 and 3.8 for Pio from the left data point respectively. The results are representative of
ﬁve independent blots. (D) The recruitment of CBP to PPARγ in the presence or absence of FPP (50 or 100μM) and GW9662 (25μM) was determined by ELISA. All the values are means+ −S.E.M.
for three to ﬁve tests. *P <0.05, **P <0.01.
Figure 3 FPP can directly bind to PPARγ as an agonist in a docking simulation study
(A) Modelling of the docking position of FPP in PPARγ protein by referring to the X-ray crystal structure of the 5HE–PPARγ complex. FPP (green carbon atoms) and 5HE (white carbon atoms) are
represented as a stick model. The protein surface is shown in the colour of the atom. Colours: grey, carbon; red, oxygen; blue, nitrogen; yellow, sulfur. The α-helix by which the ligand-binding site
is covered is represented by a red Cα-trace model. (B) RMSD of carbon atoms for FPP (green) and 5HE (red). Each complex structure during simulation is overlapped on the structure at 15000 ps
with Cα root-mean-square ﬁtting. (C) Difference between MD-simulated pose at 15000 ps (ball and stick model) and the initial pose of MD simulation (stick model).
Figure 4 The addition of FPP up-regulates PPARγ target genes and promotes de novo fatty acid synthesis
(A–D)Expressionlevelsofadipogenicmarkergenes,suchasaP2(A),LPL(B),adiponectin(C)andGLUT4(D),in3T3-L1cellstreatedwithorwithoutFPP.3T3-L1cellswereinducedtodifferentiate
with or without 0.01μM/1μMF P Po r5μM Pio for 48h. Total RNA was isolated and analysed by real-time monitoring RT–PCR. mRNA expression levels of each gene were normalized to the
expression levels of the ribosomal 36B4 gene. The expression level of cells treated with the vehicle control is set at 100% and relative expression levels are presented as the fold inductions over
the vehicle control. (E)R a t eo fde novo fatty acid synthesis from glucose after chronic FPP treatment during adipocyte differentiation. 3T3-L1 cells were induced to differentiate and maintained
with or without 1μMF P Po r1μM Pio for 10days. Cells were analysed using [13C6]-glucose and the LC/MS system as described in the Materials and methods section. All of the values are
means+ −S.E.M. for ﬁve or six tests. *P <0.05, **P <0.01 compared with vehicle controls.
fatty acid (palmitate, stearate and oleate) synthesis, particularly
palimitate synthesis, was signiﬁcantly up-regulated compared
with vehicle administration (Figure 4E). A similar effect was
observed in the case of Pio treatment. These ﬁndings indicate
that FPP treatment enhances PPARγ target gene expression and
denovofattyacidsynthesis,leadingtothepromotionofadipocyte
differentiation.
Endogenous FPP might regulate PPARγ activity during induction of
adipocyte differentiation
To assess whether FPP produced endogenously affects
adipocyte differentiation, we measured the aP2 expression
level in the presence of inhibitors of the mevalonate
pathway. We used two inhibitors, lovastatin for HMG-CoA
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Figure 5 Endogenous FPP might regulate PPARγ activity during induction
of adipocyte differentiation
(A)IntracellularFPPlevelsinNIH3T3cellstreatedwithorwithoutlovastatin(Lova)orzaragozic
acid (ZA). NIH 3T3 cells treated with vehicle control, 10 μM Lova or 1μM ZA for 48h were
extracted with butanol/75mM ammonium hydroxide/ethanol (1:1.25:2.75, by vol.) and the
intracellular FPP level was determined as described in the Materials and methods section. All
of the values are means+ −S.E.M. for three tests. (B) mRNA expression levels of aP2, LPL and
adiponectin in 3T3-L1 cells treated with or without Lova or ZA. 3T3-L1 cells were induced
to differentiate with vehicle control, Lova (5 or 10 μM) or ZA (0.5 or 1 μM) for 48 h. mRNA
expression levels were determined as described in Figure 4. All the values are means+ −S.E.M.
for four to six tests. *P <0.05, **P <0.01 compared with vehicle controls.
(3-hydroxy-3-methylglutaryl-CoA) reductase catalysing the
conversion of HMG-CoA into mevalonate, and zaragozic acid for
squalene synthase catalysing the conversion of FPP into squalene
(Figure1A).Aspreviouslyreported[29],inthepresenceoflovast-
atin, the intracellular FPP level decreased, whereas it increased in
the presence of zaragozic acid in NIH 3T3 ﬁbroblasts, which can
differentiate to adipocytes by the ectopic expression of PPARγ
[34](Figure5A).TheintracellularFPPleveldecreasedby88.4%
in the presence of 10 μM lovastatin. On the other hand, 1 μM
zaragozic acid induced a 49-fold increase in the intracellular FPP
level.Wethentreated3T3-L1cellswiththeseinhibitorsduringthe
induction of adipocyte differentiation, and measured the mRNA
expression level of PPARγ target genes (aP2, LPL and adipon-
ectin). As shown in Figure 5(B), the addition of 10 μM lovastatin
decreased the mRNA expression levels of PPARγ target genes
(54%,3 8 % and 29% decreases in aP2, LPL and adiponectin
expressionlevelsrespectively).Conversely,thesegeneexpression
levels were increased by zaragozic acid in a dose-dependent
Figure 6 FPP promotes lipid accumulation during adipocyte differentiation
(A, B) 3T3-L1 cells were induced to differentiate with or without the indicated compounds
for 48h. The cells were incubated with or without the indicated compounds for an additional
2 days. The cells were ﬁxed with formalin, and stained with Oil Red O. Microscopy views of
representative 3T3-L1 cells (the original magniﬁcation is ×100) (A). Oil Red O was extracted
from the cells with isopropyl alcohol and attenuance was measured at 490nm (B). The levels
of Oil Red O staining were corrected for the levels of non-speciﬁc binding levels of the stain to
untreated cells. The values are means+ −S.E.M. for four tests. *P <0.05, **P <0.01.
manner;1 μMzaragozicacidincreasedaP2,LPLandadiponectin
mRNA expression levels by 2.5-, 1.6- and 1.5-fold respectively.
TheseﬁndingsindicatethatendogenousFPPcanregulatePPARγ
activity during the induction of adipocyte differentiation.
FPP promotes lipid accumulation during adipocyte differentiation
Finally, to investigate the effect of FPP on lipid accumulation
during adipocyte differentiation, we performed Oil Red O
staining. The addition of 1 μM FPP and zaragozic acid enhanced
lipid accumulation during adipocyte differentiation (1.4- and
1.3-fold increases respectively; Figures 6A and 6B). This
enhancement of lipid accumulation was cancelled in the presence
of the PPARγ antagonist GW9662. Moreover, the lovastatin-
induced decrease in lipid accumulation level was rescued by
adding FPP, but not zaragozic acid. These ﬁndings suggest that
FPPpromoteslipidaccumulationduringadipocytedifferentiation
through PPARγ activation.
DISCUSSION
Isoprenoidsmakeupalargegroupofessentialmoleculesinvolved
in diverse cellular processes including energy metabolism [10–
14]. In all metazoan organisms, isoprenoids are produced via the
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mevalonate pathway. Thus, in the present study, we assessed
the effects of various mevalonate metabolites on PPARγ activity,
which plays an important role in adipocyte differentiation. We
have reported that one of the mevalonate metabolites, FPP, which
is the precursor of almost all isoprenoids and is positioned at
branch points leading to the synthesis of other longer-chain
isoprenoids [35], enhances the expression levels of adipogenic
genes, such as aP2, LPL, adiponectin and GLUT4, suggesting
that the addition of FPP promoted adipocyte differentiation.
FPP plays an important role as the substrate of protein
farnesylation reactions catalysed by FPTase [36]. Members of
the Ras GTPase family are major substrates of post-translational
modiﬁcation by farnesylation, a process essential for their proper
membrane localization and activation [37]. Previously, Klemm
et al. [38] suggested that protein farnesylation is an essential pro-
cessinadipocytedifferentiation.Thustheincreaseinfarnesylated
protein level induced by FPP treatment might also contribute
to the promoting effect of FPP on adipocyte differentiation. In
our preliminary study, we tried the experiment using an inhibitor
of farnesyltransferase (α-hydroxy farnesyl phosphonic acid) to
elucidate the contribution of protein farnesylation. This inhibitor
(1 μM) signiﬁcantly inhibited the mRNA expression level of an
adipogenic marker gene (aP2) during adipocyte differentiation,
and this inhibitory effect was rescued by FPP treatment (1 μM).
Undertheseconditions,itissuggestedthatthefarnesyltransferase
reactionhardlyproceeds,becausethebindingabilityofα-hydroxy
farnesylphosphonicacidtofarnesyltransferaseis10-foldstronger
than that of FPP [39]. These results might indicate that FPP
induces adipogenic marker genes without affecting protein farne-
sylation. Besides serving as the substrate of post-translational
modiﬁcation, FPP has been reported to have several bioactivities
by itself [40,41]. A direct interaction between FPP and
PPARγ was determined by a co-activator recruitment assay
and docking simulation studies. Many novel ligands were studied
by these methods as well [42–44]. Compared with Pio or
troglitazone, which are potent PPARγ agonists, the Kd of FPP
waslarger.However,theKd ofFPPseemstobesmallerthanthose
of fatty acids such as linoleic acid, which are known to be PPARγ
endogenous ligands [44]. As the ability of the polar heads of
ligandstoformhydrogenbondswithPPARγ isimportant[44],the
phosphoricacidofFPPmayplayaroleinforminghydrogenbonds
with PPARγ strongly similarly to carbonic acid of fatty acids. On
the other hand, an hydrophobic interaction between the tails of
ligands and pockets of PPARγ is also required. Indomethacin,
which has a short chain, or palmitic acid, which has a ﬂexible
chain,losesentropy,resultinginaweakinteraction.Itissuggested
thatFPPhasasuitablelengthofchains,butﬂexibilitymayslightly
decrease the ability to bind the hydrophobic pockets of PPARγ.
Indeed, both glucose and lipid metabolisms of adipocytes were
activated by adding FPP. Therefore, at least partially, FPP seems
to promote adipocyte differentiation via the activation of PPARγ
as an agonist, although further studies are required to clarify the
detailed mechanisms.
In the present study, Pio and FPP vary in their relative size
of effect (FPP>Pio for some genes, FPP<Pio for others), and
palmitate accumulation is observed rather than oleate in the
case of FPP. The molecular mechanism of the agonist-dependent
transactivation of PPARγ is said to be not uniform but dependent
ontheagonisttypeandspeciﬁccofactors.Ithasbeenreportedthat
Fmoc(ﬂuoren-9-ylmethoxycarbonyl)-L-leucineactsasaselective
PPARγ ligand and potently improves insulin resistance despite
a weak induction of the mRNA expression of PPARγ target
genes in WAT [45]. In that paper, Fmoc-L-leucine interacts
with the ligand-binding site of PPARγ in a different manner
from thiazolidinediones to result in the recruitment of different
cofactors. This recruitment of different cofactors was shown
between troglitazone and 15-deoxy- 
12,14-prostaglandin J2 in
spite of the equal potential in the transactivation of PPARγ
[46]. Moreover, Camp et al. [47] reported that troglitazone,
but not rosiglitazone, may behave as a partial agonist under
certain physiological circumstances and as a full agonist in
others. As for SCD (stearoyl-CoA desaturase), rosiglitazone
has been reported to enhance SCD expression [48], whereas
troglitazone and Pio have been reported to down-regulate SCD
expression [49]. Thus it is likely that the increase in PPARγ-
mediated gene expression levels in WAT is not always paralleled
by amelioration of metabolic disorders, and that the agonist-
dependent cofactor recruitment to PPARγ might be important for
determining target genes. Further studies are required to elucidate
the characterization of FPP as a PPARγ agonist.
As previously reported [50], an HMG-CoA reductase inhibitor,
lovastatin, inhibited the induction of PPARγ target genes
duringadipocytedifferentiationinduction.Conversely,asqualene
synthase inhibitor, zaragozic acid, promoted it. These ﬁndings
indicate that mevalonate metabolites such as FPP are important
for the regulation of adipocyte differentiation induction. As is
the case for most anabolic pathways, isoprenoid biosynthesis
involving the mevalonate pathway is regulated tightly in order
to allow a constant production of various isoprenoid molecules
and to avoidoveraccumulation of toxic intermediates or products,
such as cholesterol [51]. The feedback regulation of isoprenoid
biosynthesis by cholesterol is achieved predominantly through
the repression of transcription of genes that govern the synthesis
of cholesterol, such as HMG-CoA reductase and HMG-CoA
synthase [51]. This transcriptional regulation is performed by
SREBPs (sterol-regulatory-element-binding proteins), which are
transcriptionfactorsundertheconditionsofcholesterolstarvation
[51]. There is substantial evidence that most, if not all, enzymes
of isoprenoid and cholesterol biosynthesis are under co-ordinated
regulation by SREBPs, since the overexpression of these proteins
in mice induces the expression of all enzymes involved in
isoprenoidandcholesterolbiosynthesesstudied[52].Intheobese
Zucker rat adipocytes, the expression level of the nuclear-active
form of SREBP2 was found to be elevated compared with that
in lean controls [53]. In agreement with that paper, in vivo
experiments showed that cholesterol synthesis was found to be
enhanced in the adipose tissue from obese rodents and humans
[54]. In adipocyte differentiation, SREBP1 plays a key role [55]
and the overexpression of SREBP1 in 3T3-L1-generated ligands
for PPARγ, suggesting that PPARγ ligands are generated during
isoprenoid and cholesterol biosyntheses in adipocytes [56]. In our
preliminary study, the expression level of FPP synthase, which
catalyses the conversion from geranyl pyrophosphate into FPP,
was increased in parallel with adipocyte differentiation. These
ﬁndings indicate that the isoprenoid and cholesterol biosynthesis
pathways are ﬂexibly regulated during adipocyte differentiation.
Therefore there is a possibility that a regulatory mechanism
for them is important for adipocyte differentiation. Although
further studies are required, these papers raise the possibility
that FPP stimulates PPARγ as an endogenously produced
agonist.
In the present study, lovastatin treatment inhibited adipocyte
differentiation. Although there have been a number of clinical
reports indicating that statins affect insulin sensitivity, this is
far from being an accepted fact in the ﬁeld, with an almost
equal number of reports arguing against a direct impact on any
parameters with respect to carbohydrate metabolism [57–60].
Much of the variability of observations is likely to be due to
differences in the type of statin used, the duration of treatment
and/or differences in patient populations. Even if statins inhibit
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PPARγ activity in vivo, they do not necessarily decrease insulin-
sensitivity, because not only the pharmacological activation of
PPARγ induced by thiazolidinediones, but also the reduction
in PPARγ activity prevents insulin resistance [61–64]. Thus,
depending on certain conditions, the inhibitory effects of statins
on adipocyte differentiation might be involved in the effects of
statins on insulin sensitivity.
In conclusion, the present study indicates that FPP serves
as an agonist of PPARγ in cultured adipocytes, and it might
function as an endogenous regulator of adipocyte differentiation.
The circulating FPP level in feeding dogs appears to be higher
than that in fasting dogs, raising the possibility that it is affected
by whole-body nutritional conditions [65]. Because the adipocyte
differentiation process is closely related to obesity and obesity-
associated metabolic disorders, FPP might be implicated in the
pathogenesis of these metabolic diseases.
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